Shares of Proteon Therapeutics Inc (NASDAQ:PRTO) have received a consensus recommendation of “Hold” from the six research firms that are presently covering the company, Marketbeat reports. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $2.50.
Several research analysts have weighed in on PRTO shares. Maxim Group set a $9.00 price target on Brainstorm Cell Therapeutics and gave the company a “buy” rating in a report on Thursday, March 28th. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th. Cowen reiterated a “buy” rating and issued a $149.00 price target on shares of Intercept Pharmaceuticals in a report on Wednesday, May 8th. JMP Securities downgraded Proteon Therapeutics to a “market perform” rating in a report on Thursday, March 28th. Finally, Robert W. Baird boosted their price target on Total System Services from $98.00 to $110.00 and gave the company an “outperform” rating in a report on Friday, March 29th.
Shares of NASDAQ:PRTO traded down $0.02 during trading on Friday, hitting $0.41. 199,400 shares of the stock were exchanged, compared to its average volume of 999,539. Proteon Therapeutics has a 12-month low of $0.35 and a 12-month high of $3.94. The company has a fifty day simple moving average of $0.43. The company has a market capitalization of $8.45 million, a P/E ratio of -0.36 and a beta of 0.43.
A hedge fund recently bought a new stake in Proteon Therapeutics stock. Wedbush Securities Inc. purchased a new stake in Proteon Therapeutics Inc (NASDAQ:PRTO) in the 1st quarter, according to its most recent filing with the SEC. The fund purchased 59,000 shares of the biopharmaceutical company’s stock, valued at approximately $30,000. Wedbush Securities Inc. owned about 0.30% of Proteon Therapeutics as of its most recent filing with the SEC. 22.86% of the stock is currently owned by hedge funds and other institutional investors.
About Proteon Therapeutics
Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes.
Recommended Story: Trading Stocks – What are percentage gainers?
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.